Inactive Instrument

Auris Medical Holding AG Stock price Nasdaq

Equities

CH0249375764

Biotechnology & Medical Research

Sales 2021 0.06 Sales 2022 0.31 Capitalization 5.24M
Net income 2021 -17M Net income 2022 -26M EV / Sales 2021 377,924,904 x
Net cash position 2021 408K Net Debt 2022 6.32M EV / Sales 2022 37,816,959 x
P/E ratio 2021
-1.26 x
P/E ratio 2022
-0.15 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 98.73%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Auris Medical Holding AG

Managers TitleAgeSince
Chief Executive Officer 56 03-03-31
Director of Finance/CFO 66 21-10-31
Chief Operating Officer 51 -
Members of the board TitleAgeSince
Director/Board Member 66 16-03-31
Director/Board Member 75 18-02-28
Director/Board Member 59 17-03-31
More insiders
Altamira Therapeutics Ltd. is a Bermuda-based company engaged in developing ribonucleic acid (RNA)-based therapeutics for extrahepatic targets (OligoPhore/SemaPhore delivery platforms). The Company has two flagship short interfering (siRNA) programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. The delivery platform is also suited for messenger RNA (mRNA) and other types of RNA therapeutics and is focused to be leveraged via out-licensing to pharma or biotech companies. The therapeutic objective for AM-401 is to slow down KRAS driven tumor cell growth and proliferation or to stop it altogether by delivering siRNA specifically inside tumor cells for gene knock down. AM-411 is a polyplex nanoparticle delivering siRNA to inflamed tissues to target the NF-kB signaling pathway, a critical regulator of immune and inflammatory responses. Like AM-401, the drug product is based on its OligoPhore technology.
More about the company
  1. Stock
  2. Equities
  3. Stock Altamira Therapeutics Ltd.
  4. Stock Auris Medical Holding AG - Nasdaq